Guangyu Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Guangyu Wang has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
- Tongsen Zheng
Department of Gastrointestinal Medical Oncology Harbin Medical University Cancer Hospital Harbin China
97 shared publications - Jiaqi Shi
Heilongjiang Province Key Laboratory of Molecular Oncology, Harbin, China
95 shared publications - Meng Zhou
Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China
95 shared publications - Ruisi Na
Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China
95 shared publications - Ying Guo
Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China
95 shared publications - Ying Zhao
Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China
95 shared publications
Latest Publications
Liposomal irinotecan and capecitabine plus bevacizumab as second‐line therapy in metastatic colorectal cancer: A multicenter, single‐arm study
Background: Liposomal irinotecan, characterized by its favorable pharmacologic properties and reduced systemic toxicity compared to irinotecan, has demonstrated superior therapeutic potential. This multicenter, single‐arm study was conducted to evaluate the efficacy and safety of liposomal irinotecan, capecitabine, and bevacizumab as a second‐line treatment for metastatic colorectal cancer (mCRC). Methods: Patients with histologically confirmed mCRC who had progressed following first‐line oxaliplatin‐based chemotherapy were enrolled in this study. The treatment regimen was liposomal irinotecan (70 mg/m 2 , d1), capecitabine (1000 mg/m 2 , twice daily, d1‐10), and bevacizumab (5 mg/kg, d1). The primary endpoint was progression‐free survival. Secondary endpoints included objective response rate, disease control rate, duration of response, overall survival, and safety. Results: Between March 2024 and July 2024, 63 patients were enrolled, with a median age of 60.0 years (range: 37.0‐79.0). Among the patients who received at least one tumor assessment, the objective response rate and disease control rate were 22.9% (11/48; 95% CI, 12.0‐37.3) and 89.6% (43/48; 95% CI, 77.3‐96.5), respectively. With a median follow‐up of 16.2 months (range: 0.5‐28.5), the median progression‐free survival was 8.1 months (95% CI, 7.3‐8.9), and the median overall survival was 19.5 months (95% CI, 15.2‐23.8). The most common grade 3 to 4 adverse events were diarrhea (12.7%), neutropenia (11.1%), and fatigue (6.3%). Conclusions: The combination of liposomal irinotecan, capecitabine, and bevacizumab demonstrated promising antitumor activity and a manageable safety profile in patients with mCRC who had failed first‐line oxaliplatin‐based therapy. These results suggested that this regimen is a clinically feasible second‐line treatment option for mCRC.
Liposomal irinotecan and capecitabine plus bevacizumab as second‐line therapy in metastatic colorectal cancer: A multicenter, single‐arm study
Background: Liposomal irinotecan, characterized by its favorable pharmacologic properties and reduced systemic toxicity compared to irinotecan, has demonstrated superior therapeutic potential. This multicenter, single‐arm study was conducted to evaluate the efficacy and safety of liposomal irinotecan, capecitabine, and bevacizumab as a second‐line treatment for metastatic colorectal cancer (mCRC). Methods: Patients with histologically confirmed mCRC who had progressed following first‐line oxaliplatin‐based chemotherapy were enrolled in this study. The treatment regimen was liposomal irinotecan (70 mg/m 2 , d1), capecitabine (1000 mg/m 2 , twice daily, d1‐10), and bevacizumab (5 mg/kg, d1). The primary endpoint was progression‐free survival. Secondary endpoints included objective response rate, disease control rate, duration of response, overall survival, and safety. Results: Between March 2024 and July 2024, 63 patients were enrolled, with a median age of 60.0 years (range: 37.0‐79.0). Among the patients who received at least one tumor assessment, the objective response rate and disease control rate were 22.9% (11/48; 95% CI, 12.0‐37.3) and 89.6% (43/48; 95% CI, 77.3‐96.5), respectively. With a median follow‐up of 16.2 months (range: 0.5‐28.5), the median progression‐free survival was 8.1 months (95% CI, 7.3‐8.9), and the median overall survival was 19.5 months (95% CI, 15.2‐23.8). The most common grade 3 to 4 adverse events were diarrhea (12.7%), neutropenia (11.1%), and fatigue (6.3%). Conclusions: The combination of liposomal irinotecan, capecitabine, and bevacizumab demonstrated promising antitumor activity and a manageable safety profile in patients with mCRC who had failed first‐line oxaliplatin‐based therapy. These results suggested that this regimen is a clinically feasible second‐line treatment option for mCRC.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S6 from Mapping of the T-cell Landscape of Biliary Tract Cancer Unravels Anatomic Subtype-Specific Heterogeneity
List of signature genes expressed in BTC T cell clusters.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Mapping of the T-cell Landscape of Biliary Tract Cancer Unravels Anatomic Subtype-Specific Heterogeneity
List of signature genes expressed in BTC T cell clusters.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Mapping of the T-cell Landscape of Biliary Tract Cancer Unravels Anatomic Subtype-Specific Heterogeneity
The distribution of T cell clusters in tissue origin.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Mapping of the T-cell Landscape of Biliary Tract Cancer Unravels Anatomic Subtype-Specific Heterogeneity
The distribution of T cell clusters in tissue origin.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Mapping of the T-cell Landscape of Biliary Tract Cancer Unravels Anatomic Subtype-Specific Heterogeneity
Table S3 from Mapping of the T-cell Landscape of Biliary Tract Cancer Unravels Anatomic Subtype-Specific Heterogeneity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Mapping of the T-cell Landscape of Biliary Tract Cancer Unravels Anatomic Subtype-Specific Heterogeneity
Table S3 from Mapping of the T-cell Landscape of Biliary Tract Cancer Unravels Anatomic Subtype-Specific Heterogeneity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Mapping of the T-cell Landscape of Biliary Tract Cancer Unravels Anatomic Subtype-Specific Heterogeneity
The transcriptome differences of TIL-T among different anatomical subtypes of BTC.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Mapping of the T-cell Landscape of Biliary Tract Cancer Unravels Anatomic Subtype-Specific Heterogeneity
The transcriptome differences of TIL-T among different anatomical subtypes of BTC.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Mapping of the T-cell Landscape of Biliary Tract Cancer Unravels Anatomic Subtype-Specific Heterogeneity
Immune phenotypes and TLS mature states were correlated with anatomical subtypes in BTC.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Mapping of the T-cell Landscape of Biliary Tract Cancer Unravels Anatomic Subtype-Specific Heterogeneity
Immune phenotypes and TLS mature states were correlated with anatomical subtypes in BTC.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S7 from Mapping of the T-cell Landscape of Biliary Tract Cancer Unravels Anatomic Subtype-Specific Heterogeneity
Differentially expressed genes in ICC, ECC and GBC, respectively.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Mapping of the T-cell Landscape of Biliary Tract Cancer Unravels Anatomic Subtype-Specific Heterogeneity
Differentially expressed genes in ICC, ECC and GBC, respectively.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S9 from Mapping of the T-cell Landscape of Biliary Tract Cancer Unravels Anatomic Subtype-Specific Heterogeneity
The predicted binding sites of transcription factors identified from scRNA-seq data on the CXCL13, utilizing the JASPAR database.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from Mapping of the T-cell Landscape of Biliary Tract Cancer Unravels Anatomic Subtype-Specific Heterogeneity
The predicted binding sites of transcription factors identified from scRNA-seq data on the CXCL13, utilizing the JASPAR database.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Mapping of the T-cell Landscape of Biliary Tract Cancer Unravels Anatomic Subtype-Specific Heterogeneity
The TCR overlap pattern of TIL-T among different anatomical subtypes of BTC.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Mapping of the T-cell Landscape of Biliary Tract Cancer Unravels Anatomic Subtype-Specific Heterogeneity
The TCR overlap pattern of TIL-T among different anatomical subtypes of BTC.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Mapping of the T-cell Landscape of Biliary Tract Cancer Unravels Anatomic Subtype-Specific Heterogeneity
The CXCL13+ T cells are associated with the maturation of TLS in ECC.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Mapping of the T-cell Landscape of Biliary Tract Cancer Unravels Anatomic Subtype-Specific Heterogeneity
The CXCL13+ T cells are associated with the maturation of TLS in ECC.